SEC Form 4 · STOCK Act

Insider buys that paid off for the people who copied them.

$ZSTK

ZeroStack Corp.

+206.0%

Michael Heinrich, Executive Chair, bought $3.5M. Filed Jul 20, 6:31 PM ET.

COPIED JUL 21

$1,000 copied at the first price after the filing (Jul 21 open, $1.66) was $3,060 30 trading days later.

Example. Of 339 buys of $100K or more filed Jun 29 to Sep 11, the median lost 5.3% and 67.8% lost money over the same 30 trading days. Not investment advice.

Officers and directors must report their own stock purchases within two business days. We list every one, largest first, with what copying it would have returned.

A free account keeps a watchlist. No password: we email you a link.

TRDASell

Entrada Therapeutics, Inc.

MPM BIOVENTURES 2018, L.P. · 10% owner

$1.9M−6.3%Sep 9
TRDASell

Entrada Therapeutics, Inc.

MPM BioVentures 2014, L.P. · 10% owner

$1.9M−6.3%Sep 9
TRDASell

Entrada Therapeutics, Inc.

MPM BIOVENTURES 2018, L.P. · 10% owner

$617K−2.0%Sep 3
TRDASell

Entrada Therapeutics, Inc.

MPM BioVentures 2014, L.P. · 10% owner

$617K−2.0%Sep 3
TRDASell

Entrada Therapeutics, Inc.

MPM BIOVENTURES 2018, L.P. · 10% owner

$616K−2.0%Aug 31
TRDASell

Entrada Therapeutics, Inc.

MPM BioVentures 2014, L.P. · 10% owner

$616K−2.0%Aug 31
TRDASell

Entrada Therapeutics, Inc.

MPM BioVentures 2014, L.P. · 10% owner

$462K−1.4%Aug 27
TRDASell

Entrada Therapeutics, Inc.

MPM BIOVENTURES 2018, L.P. · 10% owner

$462K−1.4%Aug 27
TRDASell

Entrada Therapeutics, Inc.

Kush Parmar · Director

$1.1M−5.5%Aug 10
TRDASell

Entrada Therapeutics, Inc.

5AM Ventures V, L.P. · 10% owner

$432K−2.2%Aug 10
TRDASell

Entrada Therapeutics, Inc.

5AM Ventures V, L.P. · 10% owner

$807K−3.9%Aug 3
TRDASell

Entrada Therapeutics, Inc.

Kush Parmar · Director

$807K−3.9%Aug 3
TRDASell

Entrada Therapeutics, Inc.

Natarajan Sethuraman · Pres, Research, Develop.

$399K−11.0%May 4
TRDASell

Entrada Therapeutics, Inc.

Nathan J Dowden · President and COO

$230K−7.0%May 4
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$32K−2.0%Apr 2
TRDASell

Entrada Therapeutics, Inc.

Nathan J Dowden · President and COO

$196K−7.0%Mar 11
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$214K−12.0%Mar 11
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$98K−5.0%Mar 6
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$89K−7.0%Nov 24
TRDASell

Entrada Therapeutics, Inc.

Natarajan Sethuraman · Pres, Research, Develop.

$82K−2.0%Nov 13
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$173K−10.0%Nov 13
TRDASell

Entrada Therapeutics, Inc.

Natarajan Sethuraman · Pres, Research, Develop.

$339K−10.0%Nov 6
TRDASell

Entrada Therapeutics, Inc.

Nathan J Dowden · President and COO

$35K−2.0%Sep 10
TRDASell

Entrada Therapeutics, Inc.

Natarajan Sethuraman · Chief Scientific Officer

$49K−2.0%Sep 10
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$48K−4.0%Sep 10
TRDASell

Entrada Therapeutics, Inc.

Nathan J Dowden · President and COO

$441K−17.0%Aug 20
TRDASell

Entrada Therapeutics, Inc.

Dipal Doshi · CEO

$34K−1.0%Jul 16
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$26K−2.0%Jul 10
TRDASell

Entrada Therapeutics, Inc.

Natarajan Sethuraman · Chief Scientific Officer

$288K−9.0%May 20
TRDASell

Entrada Therapeutics, Inc.

Dipal Doshi · CEO

$45K−1.0%May 20
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$50K−5.0%Mar 8
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$195K−20.0%Dec 26
TRDASell

Entrada Therapeutics, Inc.

Nerissa Kreher · Chief Medical Officer

$394K−50.0%Aug 4
TRDASell

Entrada Therapeutics, Inc.

Nathan J Dowden · COO

$128K−17.0%Jul 12
TRDASell

Entrada Therapeutics, Inc.

Natarajan Sethuraman · Chief Scientific Officer

$322K−10.0%Jul 12
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$180K−21.0%Jul 12
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$263K−38.0%Jun 23
TRDASell

Entrada Therapeutics, Inc.

Nathan J Dowden · COO

$246K−27.0%Jun 22
TRDASell

Entrada Therapeutics, Inc.

Dipal Doshi · President and CEO

$27K−1.0%May 1
TRDASell

Entrada Therapeutics, Inc.

Natarajan Sethuraman · Chief Scientific Officer

$71K−2.0%Apr 19
TRDASell

Entrada Therapeutics, Inc.

Dipal Doshi · President and CEO

$38K−1.0%Apr 19
TRDASell

Entrada Therapeutics, Inc.

Dipal Doshi · President and CEO

$29K−1.0%Mar 29
TRDASell

Entrada Therapeutics, Inc.

Dipal Doshi · President and CEO

$36K−1.0%Jan 10
TRDASell

Entrada Therapeutics, Inc.

Nerissa Kreher · Chief Medical Officer

$70K−25.0%Jan 3
TRDASell

Entrada Therapeutics, Inc.

Dipal Doshi · President and CEO

$219K−8.0%Dec 29
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$86K−22.0%Dec 12
TRDASell

Entrada Therapeutics, Inc.

Kory James Wentworth · CFO

$57K−16.0%Dec 6
TRDASell

Entrada Therapeutics, Inc.

Dipal Doshi · President and CEO

$28K−1.0%Nov 30
TRDASell

Entrada Therapeutics, Inc.

Nathan J Dowden · COO

$50K−4.0%Nov 2
TRDASell

Entrada Therapeutics, Inc.

Nathan J Dowden · COO

$194K−16.0%Oct 27

Filings come from SEC EDGAR within a minute of the SEC accepting them. Without Pro, each one unlocks 4 hours later. Not investment advice.

Questions

Where does the data come from?

Corporate insider trades come straight from SEC Form 4 filings, pulled from EDGAR within a minute of each filing. Congress trades come from STOCK Act disclosures. All of it is public and free to browse here, and Pro sees the newest filings first.

How often is it updated?

Every minute from 6 AM to 10 PM New York time on weekdays, the hours the SEC accepts filings. Pro sees each filing as it lands. Without Pro, a filing unlocks 4 hours after the SEC accepts it.

Is following insider trades legal?

Yes. Insiders are legally required to disclose their trades within a few days. Acting on those public disclosures is completely legal. Trading on private, non-public information is illegal, but that's a different thing.

What does the iPhone app add?

We're building an iPhone app that alerts you to new filings and, if you choose, copies a buy into your own brokerage after you approve it. It isn't out yet, and the waitlist is free.